11.51
0.11 (0.96%)
0.11 (0.96%)
Upgrade to Real-Time
Afterhours (Closed)
| Volume | 1,504,109 |
|
|||||
| News | - | ||||||
| Day High | 11.63 | Low High |
|||||
| Day Low | 11.12 | ||||||
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Allogene Therapeutics Inc | ALLO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
 |
|
|---|---|---|---|---|
| 0.11 | 0.96% | 11.51 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 11.37 | 11.12 | 11.63 | 11.51 | 11.40 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 17,548 | 1,504,109 | $ 11.36 | $ 17,080,508 | - | 6.425 - 27.86 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:42:08 | 1 | $ 12.03 | USD |
Period:
Draw Mode:
Allogene Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 1.65B | 143.60M | 89.61M | $ 38.49M | $ - | -1.89 | -5.20 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 5.98M | 3.40% |
Allogene Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALLO Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 12.19 | 12.50 | 11.01 | 11.89 | 2,540,365 | -0.68 | -5.58% |
| 1 Month | 7.81 | 12.50 | 7.80 | 10.67 | 2,828,359 | 3.70 | 47.38% |
| 3 Months | 9.24 | 12.50 | 6.425 | 9.15 | 2,204,316 | 2.27 | 24.57% |
| 6 Months | 14.95 | 15.40 | 6.425 | 9.73 | 1,919,992 | -3.44 | -23.01% |
| 1 Year | 26.03 | 27.86 | 6.425 | 13.29 | 1,664,879 | -14.52 | -55.78% |
| 3 Years | 26.71 | 55.00 | 6.425 | 22.43 | 1,079,147 | -15.20 | -56.91% |
| 5 Years | 22.00 | 55.00 | 6.425 | 22.94 | 981,691 | -10.49 | -47.68% |
Allogene Therapeutics Description
| Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies. |